VCs Put $15M Into New Start-Up From Proteolix Founder
This article was originally published in The Pink Sheet Daily
The biotech, Arvinas, will pursue therapies that degrade proteins, a process that could lead to therapeutic approaches to targets previously thought to be undruggable. The $15 million in venture funding is augmented by $3.5 million from the state of Connecticut.
You may also be interested in...
Arvinas’ proprietary work has been in oncology, with a prostate cancer candidate slated to enter the clinic in 2016, but the collaboration with Merck will focus on a variety of targets and therapeutic areas.
The beginnings of ominous signs are appearing in the flourishing biotech IPO market. Plus news on recent financings by Foundation Medicine, Arvinas, Moderna Therapeutics and Frazier Healthcare.
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.